The effect of valacyclovir [VALTREX] 1g once daily on HSV-2 [herpes simplex virus] viral shedding in subjects newly diagnosed with genital herpes infection

Trial Profile

The effect of valacyclovir [VALTREX] 1g once daily on HSV-2 [herpes simplex virus] viral shedding in subjects newly diagnosed with genital herpes infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes genitalis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Nov 2006 Status change
    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top